Iktos
AI de novo molecular design platform for drug discovery that generates novel chemical structures with desired properties.
What it does
Iktos is an AI-native drug design company developing generative AI software for de novo molecular design - creating novel chemical structures from scratch that meet specified drug-like properties rather than screening existing compound libraries. Its Makya platform uses deep generative models trained on medicinal chemistry knowledge to propose new molecular scaffolds and analogs optimized for target binding, ADMET properties, and synthetic accessibility. AI capabilities include generative molecular design that creates novel compounds from property specifications, multi-parameter optimization that balances multiple drug-like properties simultaneously, retrosynthesis planning that assesses the synthetic feasibility of generated compounds, virtual screening that evaluates generated compounds against target models, and active learning loops that incorporate wet lab experimental data to guide subsequent design iterations.
Why AI-NATIVE
Iktos is AI-native - generative deep learning molecular design that creates novel chemical structures from scratch based on desired property profiles is the core product architecture.
Best for
Biotech drug discovery teams use Iktos for AI-guided medicinal chemistry - generative design exploring vast chemical space faster than traditional analog synthesis approaches.
Large pharmaceutical companies use Iktos for AI drug design programs - generative chemistry integrated with experimental workflows to accelerate lead optimization in preclinical drug discovery.
Limitations
Iktos's generative design platform is most effective in the hands of medicinal chemists who can evaluate AI-proposed structures for practical synthesis feasibility and biological plausibility.
AI-designed structures must be synthesized and tested in the laboratory — generative design accelerates the search for candidates but does not eliminate the need for wet lab validation.
Iktos competes against well-funded AI drug design platforms and established computational chemistry vendors — pharmaceutical buyers have multiple credible options for AI-assisted molecular design.
Alternatives by segment
| If you need… | Consider instead |
|---|---|
| Integrated computational drug design | Schrodinger |
| AI-first drug design company | Exscientia |
| Laboratory informatics platform | Benchling |
Iktos Makya platform licensing for pharmaceutical companies. Not published. Annual contracts. Partnership and collaboration models also available.
